October 2018—Bio-Rad announced the launch of recombinant beta-2 microglobulin from the company’s line of critical raw materials. This recombinant sourced tumor marker protein offers consistency and security over materials harvested from human sources. β2M is an 11 kD prognostic tumor marker and light chain of the class one major histocompatibility complex located on the surface of many cells. It is also found in the serum in a free form. Levels of β2M elevated in the blood are correlated with a larger amount of tumor and reduced kidney function in multiple myeloma patients.